by user | Jan 27, 2014 | Company Initiatives
Stemedica Cell Technologies, Inc. a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014. Craig Carlson brings 34 years of...
by user | Jul 10, 2013 | Clinical Trials
Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially...
by user | Mar 1, 2013 | Publications
Abstract Object. The multipotency of neural stem cells (NSCs) can be assessed in vitro by detection of stage-specific markers in response to a suitable differentiation signal. This test is frequently used because it is fast and affordable. However, it is not clear how...
by user | Jan 7, 2013 | Publications
Abstract Introduction A feature which makes stem cells promising candidates for cell therapy is their ability to migrate effectively into damaged or diseased tissues. Recent reports demonstrated the increased motility of human mesenchymal stem cells (hMSC) grown under...
by user | Oct 16, 2012 | Publications
Abstract Background context Spinal cord injury can lead to severe functional impairments secondary to axonal damage, neuronal loss, and demyelination. The injured spinal cord has limited regrowth of damaged axons. Treatment remains controversial, given inconsistent...
